{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319600324992.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1128/aac.00605-19"}},{"identifier":{"@type":"URI","@value":"https://journals.asm.org/doi/pdf/10.1128/AAC.00605-19"}}],"dc:title":[{"@value":"Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Linezolid is administered as a fixed dose to all patients despite evidence of increased exposure and myelosuppression in renal impairment. The objectives of these studies were to assess the risk of thrombocytopenia with standard-dose linezolid in renal impairment and to identify an alternate dosing strategy.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319600325120","@type":"Researcher","foaf:name":[{"@value":"Ryan L. Crass"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319600324994","@type":"Researcher","foaf:name":[{"@value":"Pier Giorgio Cojutti"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of Udine, Udine, Italy"},{"@value":"Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, Udine, Italy"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319600324993","@type":"Researcher","foaf:name":[{"@value":"Manjunath P. Pai"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319600324992","@type":"Researcher","foaf:name":[{"@value":"Federico Pea"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of Udine, Udine, Italy"},{"@value":"Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, Udine, Italy"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00664804"},{"@type":"EISSN","@value":"10986596"}],"prism:publicationName":[{"@value":"Antimicrobial Agents and Chemotherapy"}],"dc:publisher":[{"@value":"American Society for Microbiology"}],"prism:publicationDate":"2019-08","prism:volume":"63","prism:number":"8","prism:startingPage":"e00605"},"reviewed":"false","dc:rights":["https://journals.asm.org/non-commercial-tdm-license"],"url":[{"@id":"https://journals.asm.org/doi/pdf/10.1128/AAC.00605-19"}],"createdAt":"2019-05-23","modifiedAt":"2022-02-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360294643746872960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Therapeutic drug monitoring-enabled long-term use of linezolid for the successful treatment of refractory pyogenic spondylodiscitis without development of thrombocytopenia: A case report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092862028928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232407657600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567838050304","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1128/aac.00605-19"},{"@type":"CROSSREF","@value":"10.1016/j.jos.2021.11.018_references_DOI_Z8ISE1SgwDX9CfVzJMx7MHmzpBX"},{"@type":"CROSSREF","@value":"10.1186/s40360-021-00479-w_references_DOI_Z8ISE1SgwDX9CfVzJMx7MHmzpBX"},{"@type":"CROSSREF","@value":"10.1007/s00228-023-03455-x_references_DOI_Z8ISE1SgwDX9CfVzJMx7MHmzpBX"},{"@type":"CROSSREF","@value":"10.1016/j.xphs.2021.02.014_references_DOI_Z8ISE1SgwDX9CfVzJMx7MHmzpBX"}]}